AAX Biotech CEO Pitches Next-Gen Antibody Therapies at KI Innovations InvestorDay
AAX Biotech CEO Daniel X. Johansson presented the company's advancements in antibody-based therapies at KI Innovations InvestorDay 2026. The event connected promising Swedish biotech startups with key industry investors.
Daniel X. Johansson, CEO, CSO, and Co-Founder of AAX Biotech, recently took the stage at KI Innovations InvestorDay 2026. The event, held on April 21, served as a crucial platform for showcasing Sweden's most exciting biotech startups to leading investors in the field.
Johansson's presentation highlighted AAX Biotech's pioneering work in advancing next-generation antibody-based therapies. Pitching before an experienced jury provided an invaluable opportunity for the company to gain visibility and receive sharp, objective feedback on its strategic direction and scientific trajectory.
Beyond the formal pitch, the event offered a significant chance for AAX Biotech to engage with the broader biotech community. This interaction allowed for networking, knowledge exchange, and a temporary step away from daily lab activities, fostering a collaborative environment. AAX Biotech extended its gratitude to Karolinska Institutet Innovation for orchestrating such a well-curated and impactful InvestorDay.